Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study.
Tufail A, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Cole M, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Yang Y, Andrews C, Brittain C, Osborne A.
Main finding: There was a significant improvement in BCVA and central macular thickness at 6 months in patients receiving intravitreal ranibizumab for myopic CNV.
Purpose: To evaluate the safety and efficacy of intravitreal ranibizumab in myopic CNV
Study type: Phase 2 single arm study
Condition: Myopic Choroidal Neovascularization
Participants: Age ≥18 years with active primary or recurrent subfoveal/juxtafoveal myopic CNV
-high myopia (at least -6.0dioptres)
n=65 patients
Intervention:
Intravitreal Ranibizumab 0.5mg followed by monthly injections as needed for up to 11 months
Interim analysis:
-Mean BCVA improved from baseline by 12.2 letters
-Fewer patients had centre-involving intraretinal oedema (13.0% vs 91.5%), intraretinal cysts (10.9% vs 57.4%), or subretinal fluid (13.0% vs 66.0%) at 6 months than at baseline
-Patients received a mean of 1.9 retreatments
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive